Natera Inc
NTRA230.630USD
+5.080+2.25%
Close 11/21, 16:00（ET）Quotes delayed by 15 min
31.35BMarket Cap
LossP/E TTM
More Details of Natera Inc Company
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
Natera Inc Info
Ticker SymbolNTRA
Company nameNatera Inc
IPO dateJul 02, 2015
CEOMr. Steven Leonard (Steve) Chapman
Number of employees4424
Security typeOrdinary Share
Fiscal year-endJul 02
Address13011 Mccallen Pass
CityAUSTIN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code78753
Phone16502499090
Websitehttps://www.natera.com/
Ticker SymbolNTRA
IPO dateJul 02, 2015
CEOMr. Steven Leonard (Steve) Chapman
Company Executives of Natera Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Matthew Rabinowitz, Ph.D.
Dr. Matthew Rabinowitz, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.28M
-1.72%
Mr. Roelof Frederick Botha
Mr. Roelof Frederick Botha
Lead Independent Director
Lead Independent Director
1.23M
+0.01%
Mr. Jonathan Sheena
Mr. Jonathan Sheena
Co-Founder, Director
Co-Founder, Director
305.25K
-1.00%
Mr. Daniel A Rabinowitz
Mr. Daniel A Rabinowitz
Secretary, Chief Legal Officer
Secretary, Chief Legal Officer
150.99K
-1.05%
Mr. John Fesko
Mr. John Fesko
President, Chief Business Officer
President, Chief Business Officer
86.09K
-2.32%
Herman Rosenman, CPA
Herman Rosenman, CPA
Independent Director
Independent Director
65.67K
+0.23%
Mr. Solomon Moshkevich
Mr. Solomon Moshkevich
President - Clinical Diagnostics
President - Clinical Diagnostics
37.71K
-7.37%
Dr. Monica Bertagnolli, M.D.
Dr. Monica Bertagnolli, M.D.
Independent Director
Independent Director
6.22K
+1.52%
Dr. Rowan E. Chapman, Ph.D.
Dr. Rowan E. Chapman, Ph.D.
Independent Director
Independent Director
3.18K
+4.20%
Mr. Steven Leonard (Steve) Chapman
Mr. Steven Leonard (Steve) Chapman
Chief Executive Officer, Director
Chief Executive Officer, Director
3.17K
-28.17%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Matthew Rabinowitz, Ph.D.
Dr. Matthew Rabinowitz, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.28M
-1.72%
Mr. Roelof Frederick Botha
Mr. Roelof Frederick Botha
Lead Independent Director
Lead Independent Director
1.23M
+0.01%
Mr. Jonathan Sheena
Mr. Jonathan Sheena
Co-Founder, Director
Co-Founder, Director
305.25K
-1.00%
Mr. Daniel A Rabinowitz
Mr. Daniel A Rabinowitz
Secretary, Chief Legal Officer
Secretary, Chief Legal Officer
150.99K
-1.05%
Mr. John Fesko
Mr. John Fesko
President, Chief Business Officer
President, Chief Business Officer
86.09K
-2.32%
Herman Rosenman, CPA
Herman Rosenman, CPA
Independent Director
Independent Director
65.67K
+0.23%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Insurance carriers
516.99M
94.58%
Laboratory and other partners
22.17M
4.06%
Patients
7.44M
1.36%
By RegionUSD
Name
Revenue
Proportion
United States
537.80M
98.39%
Europe, Middle East, India, Africa
5.41M
0.99%
Asia Pacific and Other
1.82M
0.33%
Americas, excluding U.S
1.57M
0.29%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Insurance carriers
516.99M
94.58%
Laboratory and other partners
22.17M
4.06%
Patients
7.44M
1.36%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.94%
T. Rowe Price Associates, Inc.
8.57%
JP Morgan Asset Management
7.02%
BlackRock Institutional Trust Company, N.A.
4.92%
Farallon Capital Management, L.L.C.
3.08%
Other
67.48%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.94%
T. Rowe Price Associates, Inc.
8.57%
JP Morgan Asset Management
7.02%
BlackRock Institutional Trust Company, N.A.
4.92%
Farallon Capital Management, L.L.C.
3.08%
Other
67.48%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.30%
Investment Advisor/Hedge Fund
27.01%
Hedge Fund
12.75%
Individual Investor
3.07%
Family Office
2.73%
Family Office
2.73%
Family Office
2.46%
Bank and Trust
1.98%
Research Firm
1.60%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1200
128.93M
93.94%
-2.81M
2025Q2
1137
131.96M
96.64%
-402.16K
2025Q1
1129
133.60M
97.90%
+2.21M
2024Q4
1001
128.40M
95.17%
-537.76K
2024Q3
896
125.06M
100.75%
-6.81M
2024Q2
850
125.13M
101.89%
-7.92M
2024Q1
798
124.30M
101.71%
-6.12M
2023Q4
781
119.55M
99.60%
-13.66M
2023Q3
787
122.52M
102.97%
-5.30M
2023Q2
792
116.72M
102.40%
-10.10M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
12.62M
9.2%
+279.77K
+2.27%
Jun 30, 2025
T. Rowe Price Associates, Inc.
12.07M
8.79%
+1.64M
+15.72%
Jun 30, 2025
JP Morgan Asset Management
8.92M
6.5%
+2.53M
+39.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.78M
4.94%
+101.02K
+1.51%
Jun 30, 2025
Farallon Capital Management, L.L.C.
4.82M
3.51%
+274.00K
+6.02%
Jun 30, 2025
State Street Investment Management (US)
3.32M
2.42%
-53.04K
-1.57%
Jun 30, 2025
Duquesne Family Office LLC
3.09M
2.25%
-317.14K
-9.32%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.55M
1.86%
+166.77K
+6.99%
Jun 30, 2025
Franklin Advisers, Inc.
1.93M
1.41%
+330.96K
+20.65%
Jun 30, 2025
Wellington Management Company, LLP
2.63M
1.92%
-426.00K
-13.92%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Franklin Genomic Advancements ETF
6.11%
Alger Weatherbie Enduring Growth ETF
5.61%
VanEck Biotech ETF
4.16%
Alger 35 ETF
4.03%
ARK Genomic Revolution ETF
3.94%
Global X Genomics & Biotechnology ETF
3.85%
First Trust Nasdaq Lux Digi Health Solutions ETF
3.83%
Invesco Dorsey Wright Healthcare Momentum ETF
3.38%
TrueShares Technology, AI & Deep Learning ETF
3.21%
First Trust NYSE Arca Biotechnology Index Fund
3.12%
View more
Franklin Genomic Advancements ETF
Proportion6.11%
Alger Weatherbie Enduring Growth ETF
Proportion5.61%
VanEck Biotech ETF
Proportion4.16%
Alger 35 ETF
Proportion4.03%
ARK Genomic Revolution ETF
Proportion3.94%
Global X Genomics & Biotechnology ETF
Proportion3.85%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion3.83%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion3.38%
TrueShares Technology, AI & Deep Learning ETF
Proportion3.21%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Natera Inc?
The top five shareholders of Natera Inc are:
The Vanguard Group, Inc. holds 12.62M shares, accounting for 9.20% of the total shares.
T. Rowe Price Associates, Inc. holds 12.07M shares, accounting for 8.79% of the total shares.
JP Morgan Asset Management holds 8.92M shares, accounting for 6.50% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.78M shares, accounting for 4.94% of the total shares.
Farallon Capital Management, L.L.C. holds 4.82M shares, accounting for 3.51% of the total shares.
The Vanguard Group, Inc. holds 12.62M shares, accounting for 9.20% of the total shares.
T. Rowe Price Associates, Inc. holds 12.07M shares, accounting for 8.79% of the total shares.
JP Morgan Asset Management holds 8.92M shares, accounting for 6.50% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.78M shares, accounting for 4.94% of the total shares.
Farallon Capital Management, L.L.C. holds 4.82M shares, accounting for 3.51% of the total shares.
What are the top three shareholder types of Natera Inc?
The top three shareholder types of Natera Inc are:
The Vanguard Group, Inc.
T. Rowe Price Associates, Inc.
JP Morgan Asset Management
The Vanguard Group, Inc.
T. Rowe Price Associates, Inc.
JP Morgan Asset Management
How many institutions hold shares of Natera Inc (NTRA)?
As of 2025Q3, 1200 institutions hold shares of Natera Inc, with a combined market value of approximately 128.93M, accounting for 93.94% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -2.70%.
What is the biggest source of revenue for Natera Inc?
In FY2025Q2, the Insurance carriers business generated the highest revenue for Natera Inc, amounting to 516.99M and accounting for 94.58% of total revenue.
